Valneva IPO Presentation Deck
April 2021, 41 slides
  1. Valneva
  2. Related Decks
  3. IPO Presentation Decks
presentation | Valneva
| Valneva
offering summary | Valneva
management team | Valneva
in summary | Valneva
has three highly differentiated clinical programs and two products | Valneva
global network staff mainly in operations in | Valneva
disease vaccine | Valneva
disease is a major health issue severe tick transmitted infection increasingly common in the us and | Valneva
multivalent disease vaccine candidate only program in advanced clinical development today | Valneva
mechanism of action of based vaccines is understood anti protective response with disease vaccines | Valneva
for highest dose group in phase | Valneva
phase month schedule showed high immunogenicity rates after completion of primary vaccination series ranged from to in highest dose | Valneva
development outlook | Valneva
exclusive partnering deal with collaboration with for late stage development and future commercialization | Valneva
vaccine | Valneva
is a significant growing public health concern a mosquito borne viral outbreak disease in tropical sub tropical regions | Valneva
only vaccine candidate in phase today | Valneva
phase trial led to direct progression into phase | Valneva
phase of showed enduring high immunogenicity a single shot is sufficient to induce high titre neutralizing | Valneva
high dose vaccination protects against challenge induced aes high dose after single vaccination | Valneva
in subjects clinical data in phase clinical trial published in lancet | Valneva
development outlook pivotal phase trial topline read out expected mid | Valneva
covid | Valneva
inactivated virus technology allows for potential | Valneva
the only inactivated vaccine in clinical development in with | Valneva
was well tolerated in phase safety profile within the expected range for an inactivated vaccine ans | Valneva
was highly immunogenic in phase of trial participants developed significant levels of antibodies | Valneva
generated neutralizing antibody titers at or above levels generally seen in convalescent sera in phase | Valneva
antibody response was highly correlated with a i specific | Valneva
immunogenicity summary cellular response induced against the protein | Valneva
development outlook pivotal phase trial initiated | Valneva
collaboration to provide up to million doses of inactivated vaccine to the | Valneva
commercial products | Valneva
has a specialist travel vaccine business and is a contractor to the us military | Valneva
summary i | Valneva
company in strong position to scale its business including to mitigate and inventory build up commercial business supported by us supplements capital received from opportunity to build pipeline as current programs advance | Valneva
catalysts | Valneva
key upcoming catalysts and potential inflection points | Valneva
a session | Valneva
thank you tack | Valneva
See More
Valneva
IPO Presentation Decks
Biotechnology Decks
Healthcare Decks
Explore Topics
Vaccine
Clinical development
Clinical trial
Related decks
BioNTech
Results
August 2020
Hillevax
IPO
April 2022
BioNTech
Results
May 2021
Erasca
Investor Presentation
January 2024
BioNTech
Results
May 2020
BioNTech
Results
August 2021
RayzeBio
IPO
September 2023
Legend Biotech
Investor Presentation
April 2025
BioNTech
Results
August 2020
Hillevax
IPO
April 2022
BioNTech
Results
May 2021
Erasca
Investor Presentation
January 2024
BioNTech
Results
May 2020
BioNTech
Results
August 2021
RayzeBio
IPO
September 2023
Legend Biotech
Investor Presentation
April 2025
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights